Polyphor closes merger with EnBiotix and is renamed Spexis
Polyphor closes merger with EnBiotix and is renamed Spexis
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Polyphor closes merger with EnBiotix and is renamed Spexis
eFlow Technology Nebulisers with Digital Therapy Management: The PARI Connect Eco-System.
Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD.
Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging.
Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial.
